The Association for Frontotemporal Degeneration (AFTD)
Esther Kane, MSN, RN-CDP has a diverse work experience in the healthcare industry. Esther is currently serving as the Director of Support & Education at The Association for Frontotemporal Degeneration (AFTD) since November 2020. Prior to that, they worked as the Director of Wellness at CareOne Management LLC from September 2018 to November 2020. Esther also has experience as a Registered Nurse at Virtua Health from May 2017 to October 2018. Esther was the Wellness Director at The Clare Estate Independent & Assisted Living from September 2013 to May 2017. Esther began their career as a Marketing Director at CareOne Management LLC from November 2007 to April 2009. Before that, they worked as a Customer Service Representative at BROOKDALE SENIOR LIVING INC from April 2003 to November 2007.
Esther Kane, MSN, RN-CDP has a comprehensive education history in the field of nursing. Esther earned their Master of Science in Nursing (MSN) degree with a focus on Nursing Leadership and Education from Wilmington University between 2017 and 2021. Prior to that, they completed their Bachelor of Science in Nursing (BSN) degree at Drexel University College of Nursing & Health Professions Division of Undergraduate Nursing, graduating between 2014 and 2017. Before pursuing their BSN, Esther attended Abington Memorial Hospital Dixon School of Nursing from 2011 to 2013, where they obtained their initial Registered Nurse (RN) qualification.
In addition to their formal education, Esther has also acquired additional certifications. In 2020, they became a Certified Dementia Practitioner through the NATIONAL COUNCIL OF CERTIFIED DEMENTIA PRACTITIONERS, LLC. Esther is also a Registered Nurse in two states: Pennsylvania (obtained in September 2013) and New Jersey (specific details not provided).
This person is not in any offices
The Association for Frontotemporal Degeneration (AFTD)
AFTD establish an institution dedicated to advancing FTD research, providing information, education, and support, as well as raising awareness of this uncommon and especially devastating disease, the AFTD, in whom mission is to improve the quality of life for those affected by FTD and drive research toward a cure, collaborated with a collective ofdedicated FTD care partners and medical professionals. With a committed board of directors, a robust volunteer network, and medical and scientific advisers from the leading experts from across the world, the company has developed into a major international structure on FTD and young onset dementia. AFTD has profited from kind foundation and donor funding, including gifts from the fund.